CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• Cyclin D-CDK4/6 complexes are crucial for G1 phase progression and are targeted by therapies like palbociclib for advanced ER-positive breast cancer.
• Current limitations exist in predicting patient response to CDK4/6 inhibitors, highlighting the need for predictive biomarkers.
• Activating T172 phosphorylation of CDK4 is a key rate-limiting event signaling active CDK4 and cell cycle initiation.

Purpose of the Study:

• To investigate the role of CDK4 post-translational modifications, specifically T172 phosphorylation, in breast tumors.
• To develop and validate a gene expression signature predicting CDK4 modification profiles.
• To correlate CDK4 T172 phosphorylation and the gene signature with sensitivity to CDK4/6 inhibitors.

Main Methods:

• Analysis of post-translational modification profiles, including T172 phosphorylation of CDK4, in breast tumors.
• Development of a gene expression signature to predict CDK4 modification patterns.
• Correlation studies between CDK4 T172 phosphorylation, gene signature, and sensitivity to the CDK4/6 inhibitor PD0332991 (palbociclib) in cell lines.

Main Results:

• CDK4 T172 phosphorylation profiles vary across breast tumor subtypes and correlate with tumor risk.
• A gene expression signature accurately predicted CDK4 modification profiles in both tumors and cell lines.
• CDK4 T172 phosphorylation showed the strongest correlation with sensitivity to palbociclib in breast cancer cell lines.

Conclusions:

• The identified gene expression signature can predict CDK4 modification profiles and identify tumors unlikely to respond to CDK4/6 inhibitors.
• This signature may aid in selecting patients, including those with HER2-positive and basal-like breast tumors, for clinical trials involving CDK4/6 inhibitors.
• Understanding CDK4 modification patterns offers a potential strategy for personalized therapy selection in breast cancer treatment.